Iptacopan Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Iptacopan Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
38
Registered trials
86
Result records
3
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Iptacopan can convert its Small molecule drug profile and CFB biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Iptacopan (query alias: iptacopan) |
|---|---|
| Modality / target | Small molecule drug; CFB; CFB inhibitors |
| Highest global status | Approved |
| Originator | Novartis Pharma AG |
| Active developers | Novartis Pharmaceuticals Canada, Inc., Novartis Pharma Produktions GmbH, Novartis Pharmaceuticals Corp. |
The MCP disease footprint includes glomerulonephritis chronic complement component 3 glomerulopathy, Complement Factor H Deficiency, C3 glomerulopathy. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT06994845 | Phase 3 | Recruiting | 31 | Log-transformed ratio to Baseline in UPCR (based on FMV) |
| NCT07331259 | Not Applicable | Not yet recruiting | 83 | Demographics: Number of patients by age |
| NCT07347990 | Not Applicable | Not yet recruiting | 30 | Six-month Overall Survival Rate Following TA-TMA Diagnosis |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A MULTI-CENTER RETROSPECTIVE STUDY IN SOUTHERN CHINA
Not Applicable; n=40; evaluation: Positive. Reported fields: Hemoglobin level(increase of ≥20 g/L) = 86.0 %
LONG-TERM HEMATOLOGIC CONTROL AND SAFETY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATED WITH IPTACOPAN: 6-YEAR FOLLOW-UP FROM PHASE 2 STUDIES AND ROLL-OVER EXTENSION PROGRAM
Phase 2; n=26; evaluation: Positive. Reported fields: ARC normalization = 100.0 %
A REAL-WORLD STUDY: EFFICACY AND SAFETY OF COMPLEMENT INHIBITORS (ECULIZUMAB OR IPTACOPAN) COMBINED WITH CYCLOSPORINE IN PATIENTS WITH APLASTIC ANEMIA-PAROXYSMAL NOCTURNAL HEMOGLOBINURIA SYNDROME
Not Applicable; n=38; evaluation: Positive. Reported fields: Hb normalization = 47.1 % ; Hb normalization = 14.3 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Iptacopan addresses glomerulonephritis chronic complement component 3 glomerulopathy, Complement Factor H Deficiency, C3 glomerulopathy. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: CFB records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-06-22 | Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds | NDA/BLA | US$1,461.0M stated total |
| 2023-08-01 | Ionis axes eye disease from targets of Roche-partnered prospect after data disappoint | Phase 2 | US$75.0M upfront; US$684.0M milestones; US$759.0M stated total |
| 2010-03-30 | GSK and Isis Pharmaceuticals collaborate on RNA therapeutics for rare and infectious diseases | Phase 2 | US$35.0M upfront; US$1,500.0M milestones |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
